• Explore /
  • Poster
  • / A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).

A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).

Abstract Poster

Authors

null

Michael J. Mauro

Memorial Sloan Kettering Cancer Center, New York, NY

Michael J. Mauro , Andreas Hochhaus , Carla Boquimpani , Yosuke Minami , Alex Allepuz , Fotis Polydoros , Véronique Bédoucha , Paola Aimone , Delphine Réa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Chronic Leukemia—CML

Clinical Trial Registration Number

NCT03106779

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS7070)

DOI

10.1200/JCO.2019.37.15_suppl.TPS7070

Abstract #

TPS7070

Poster Bd #

440b

Abstract Disclosures

Similar Posters

First Author: Michael J. Mauro

First Author: Ehab L. Atallah

First Author: George Follows

Poster

2023 ASCO Annual Meeting

Report of a chronic myeloid leukemia registry in a low-and middle-income setting.

Report of a chronic myeloid leukemia registry in a low-and middle-income setting.

First Author: Nicolas Anthony Othieno-Abinya